Drug Trial Radar · NCT03428750
Effectiveness and Safety of EN3835 in the Treatment of EFP (Cellulite) in Women
Last checked: Nov 19, 2026Latest source record: Oct 8, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
423
Actual
Start
Feb 5, 2018
Primary completion
Sep 26, 2018
Study completion Sep 26, 2018
Sponsor
- Lead sponsor
- Endo USA Inc., a Keenova Therapeutics CompanyIndustry
- Sponsor type
- Industry
- First posted
- Feb 12, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Subjects will be screened for study eligibility within 14 days prior to enrolling in this study. Subjects with 2 treatment areas (bilateral buttocks) with moderate or severe levels of cellulite as independently assessed by the subject using the Patient Reported Photonumeric Cellulite Severity Scale (PR-PCSS) and by the Investigator using the Clinician Reported Photonumeric Cellulite Severity Scale (CR-PCSS) will be eligible. The eligibility of the buttocks will be confirmed on Day 1. Once the eligibility of the buttocks is confirmed, subjects will be randomly assigned to a treatment group (EN3835 0.84 mg per buttock or placebo) in a 1:1 ratio within an investigational site. Each subject will receive a treatment course which consists of up to 3 treatment visits (sessions), separated by 21 days (ie, Days 1, 22, and 43). Each treatment visit will consist of 12 injections (0.3 mL per injection of EN3835 0.07 mg/injection or placebo; 0.84 mg in 3.6 mL per buttock) in each of the two buttocks for a total volume of 7.2 mL (1.68 mg). Selection of dimples to be treated in the buttocks will be at the discretion of the Investigator. End of study will occur at study day 71.
Conditions
- Edematous Fibrosclerotic Panniculopathy (Cellulite)
Interventions
EN3835Biological
Collagenase clostridium histolyticum
PlaceboBiological
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- 2-level Composite Responders for the Target ButtockTime frame: Day 71
Locations
26 sites in 1 country. Site status is shown where the registry gives one.
Endo Clinical Trial Site #1
Scottsdale, Arizona
Endo Clinical Trial Site #2
Encinitas, California
Endo Clinical Trial Site #3
Long Beach, California
Endo Clinical Trial Site #4
Los Angeles, California
Endo Clinical Trial Site #5
Oceanside, California
Endo Clinical Trial Site #6
San Diego, California
Endo Clinical Trial Site #7
Boca Raton, Florida
Endo Clinical Trial Site #8
Largo, Florida
Endo Clinical Trial Site #9
Miami, Florida
Endo Clinical Trial Site #10
Snellville, Georgia
Endo Clinical Trial Site #11
Chicago, Illinois
Endo Clinical Trial Site #12
New Orleans, Louisiana
Endo Clinical Trial Site #13
Chestnut Hill, Massachusetts
Endo Clinical Trial Site #14
Quincy, Massachusetts
Endo Clinical Trial Site #15
Fridley, Minnesota
Endo Clinical Trial Site #16
Washington, Missouri
Endo Clinical Trial Site #17
Omaha, Nebraska
Endo Clinical Trial Site #18
Mount Kisco, New York
Endo Clinical Trial Site #21
New York, New York
Endo Clinical Trial Site #19
New York, New York
Endo Clinical Trial Site #20
New York, New York
Endo Clinical Trial Site #22
Cincinnati, Ohio
Endo Clinical Trial Site #23
Houston, Texas
Endo Clinical Trial Site #24
Pflugerville, Texas
Endo Clinical Trial Site #25
Sugar Land, Texas
Endo Clinical Trial Site #26
Charlottesville, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.